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DIABETIK KETOASIDOSIS: PENILAIAN DAPATAN TERAPEUTIK DAN
PENGETAHUAN, SIKAP DAN PRAKTIS PAKAR PERUBATAN DAN AHLI
FARMASI DI HOSPITAL PULAU PINANG
ABSTRAK
Kelaziman Diabetes Mellitus (DM) dan ko-morbiditi yang berkaitan dengannya adalah
tinggi. Walaubagaimanapun tidak terdapat protokol pengawalan untuk Diabetic
Ketoacidosis (DKA) setakat ini. Data mengenai keadaan ini juga tidak begitu sempurna.
Tujuan kajian ini ialah untuk merekodkan kadar kelaziman DKA dan dapatan
rawatannya. Ianya juga bertujuan meninjau pengetahuan, sikap dan praktis dalam
kalangan professional kesihatan yang terlibat secara langsung dalam rawatan DM dan
DKA. Untuk bahagian pertama, kajian secara restrospektif telah dijalankan di Hospital
Pulau Pinang. Profil pesakit DKA di pilih secara teknik persampelan universal
berdasarkan kriteria yang telah ditetapkan dan analisanya dijalankan dengan
menggunakan Statistical Package for Social Sciences (SPSS) version 16. Purata umur
pesakit adalah 47.7 ± 16.3 tahun dimana kebanyakannya adalah dalam kalangan orang
melayu (47%). DKA didapati lebih lazim dalam kalangan T2DM (51.5%), yang
mengalami hipertensi (54.5%) dan pesakit dislipidemik (43.0%). Kebanyakkan pesakit
mengalami loya dan muntah (61.4%) dan seringkali diiringi oleh sepsis (31.9%). Doktor
yang merawat juga mendapati 83.3% pesakit mengalami dehidrasi. Laporan makmal
menunjukkan paras glukos dalam darah ialah 30.4 ± 13.3 mmol · L-1, arterial pH 7.15 ±
0.16, arterial bicarbonate pada 9.7 ± 5.5 mmol · L-1 dan ketones pada 4.6 ± 1.7 mmol ·
L-1. Adalah juga di dapati yang pesakit baru diabetes (NDDM), pesakit yang meninggal
dunia dan dimasukkan ke ICU mempunyai keadaan DKA yang lebih serius. Didapati
xxi
rawatan awal DKA di unit rawatan kecemasan (ED) adalah tidak lengkap dan tidak
sejajar dengan garispanduan antarabangsa. Perkara yang sama di perhatikan untuk
rawatan dalam wad. Juga didapati profil biokimia yang berkaitan dengan DKA adalah
tidak berada dalam julat yang dibenarkan ketika pesakit keluar dari hospital. Selain dari
17.6% pesakit yang meninggal dunia juga didapati 13.7% pesakit tidak mempunyai
matlamat rawatan yang sempurna. Bahagian kedua kajian ini dijalankan secara
prospektif. Soal selidik telah diedarkan dalam kalangan ahli farmasi klinikal dan pakar
perubatan  di Unit Rawatan Rapi (ICU), Medical Follow Up Clinic (MFUC), and ED.
Kadar tindak balas keseluruhan soal selidik adalah 64.3% dengan sambutan yang paling
kurang dari ICU. Pengetahuan purata dan amalan responden didapati mencukupi. Doktor
ICU menunjukkan skor maksimum pengetahuan (6.4 ± 1.4) manakala nephrologists
menjaringkan maksimum dalam soalan berasaskan amalan (7.4 ± 0.9). Nephrologists
juga menunjukkan sikap yang lebih baik (39.1 ± 3.7) di antara kepakaran manakala
secara kolektif, sikap seluruh peserta juga didapati positif ke arah pendekatan
berpusatkan pesakit. Amalan ahli farmasi dan doktor adalah selari antara satu sama lain
yang walaupun ketara, tetapi masih suboptimal apabila dibandingkan dengan garis
panduan antarabangsa. Adalah didapati bahawa kadar kelaziman dan kematian DKA di
kalangan penduduk pelbagai etnik Malaysia adalah lebih tinggi daripada kadar yang
dilaporkan antarabangsa dan serantau. Walaupun amalan doktor dan ahli farmasi adalah
sederhana, ini bagaimanapun perlu  banyak pembaikan yang mudah boleh diatasi dengan
membangun atau mengguna pakai protokol.
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DIABETIC KETOACIDOSIS: EVALUATION OF THERAPEUTIC OUTCOMES
AND KNOWLEDGE, ATTITUDE AND PRACTICES OF PHYSICIANS AND
PHARMACISTS IN HOSPITAL PULAU PINANG
ABSTRACT
Incidence of Diabetes Mellitus (DM) and its associated acute co-morbidities is
increasing. However, there is no Diabetic Ketoacidosis (DKA) treatment protocol in
Malaysia at this point. There is no baseline data available for DKA in Malaysia as well.
This study aims to record incidence rate of DKA and its treatment outcomes in
Malaysian population. It is also intended to get an insight of knowledge, attitude and
practices of healthcare professionals that are directly involved in management of DM
and DKA. For first part, the study was done retrospectively at Hospital Pulau Pinang
(HPP). DKA patient profiles were recorded by using universal sampling technique based
on inclusion criteria and further analyzed using Statistical Package for Social Sciences
(SPSS)® version 16. Of total 132 DKA patients, mean age of patients was 47.7 ± 16.3
years while most admissions were attributed to Malay patients (47%). DKA was more
prevalent in T2DM (51.5%) patients followed by hypertension (54.5%) and
dyslipidemia (43.0%). Most patients (61.4%) registered complaint of nausea and
vomiting, and were accompanied with sepsis (31.9%) whereas attending physicians
observed 83.3% patients to be dehydrated. Moreover, with mean blood glucose level at
30.4 ± 13.3 mmol · L-1, arterial pH at 7.15 ± 0.16, arterial bicarbonate at 9.7 ± 5.5 mmol
· L-1 and ketones at 4.6 ± 1.7 mmol · L-1, chief DKA biochemical profiles rendered
patients to be experiencing moderate episode of DKA, on average. It was also observed
that newly diagnosed diabetes mellitus (NDDM) patients, deceased patients and ICU
referred patients had more severe event of DKA than the rest of patients. It was found
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that initial management of DKA patients in emergency department (ED) and in-patient
management were not completely at par with international guidelines. Furthermore,
biochemical profiles related to DKA were not within recommended limits at the time of
discharge. Apart from 17.6% deceased patients, 13.7% were found to be not at
recommended treatment goal. Second part of study was conducted prospectively.
Questionnaires were distributed among clinical pharmacists and physicians of Intensive
Care Unit (ICU), Medical Follow Up Clinic (MFUC), and ED. With total 92 included
questionnaires, overall response rate of questionnaire was 64.3% with least response
from ICU. Average knowledge and practices of respondents were found adequate. ICU
physicians showed maximum score of knowledge (6.4 ± 1.4) whereas nephrologists
scored maximum in practice based questions (7.4 ± 0.9). Nephrologists also showed
better attitude (39.1 ± 3.7) across specialties while collectively, attitude of rest of the
participants was also found positive toward patient centric approach. Pharmacists and
physicians practices were parallel with each other which were although appreciable;
these were still suboptimal when compared with international guidelines, however. The
incidence and mortality rates of DKA in multiethnic population of Malaysia are higher
than international and regional reported rates. Moreover, though the practices of
physicians and pharmacists are sound on average, these need plenty of improvement
which could easily be overcome by developing or adopting a protocol, however.
1CHAPTER 1
INTRODUCTION
1.1 Diabetes Mellitus
Diabetes Mellitus (DM) is a life long, chronic and to-date, an incurable disorder of
metabolic continuum that could be best defined as persistent hyperglycemia. It is among
the 10 most prevalent diseases of the world according to World Health Organization and
directly contributes in mortality rates of cardiovascular and tuberculosis related deaths
(World Health Organization., 2009). Prevalence of diabetes is increasing globally and is
estimated to affect 439 million people by the year 2030. The increase in number of
adults with diabetes is expected to be 20% and 69% for developed and developing
countries, respectively, when comparing with prevalence of DM in 2010 (Shaw et al.,
2010; IDF, 2012). This reciprocates that DM and complications attributed to DM will
increase and so will their cost of management (Umpierrez and Kitabchi, 2003; Kitabchi
et al., 2006; Mathers et al., 2008).
1.1.1 Types of Diabetes Mellitus and its complications
Diabetes is categorized in two main types namely type 1 and type 2 diabetes. In case of
destruction of beta cells present in islet cells of Langerhans, there is an absolute
deficiency of insulin production. This condition is type 1 diabetes mellitus (T1DM),
usually occurs in childhood and requires lifelong administration of insulin as a part of
management. Patients of type 2 diabetes mellitus (T2DM) have a relative deficiency of
natural insulin which is not sufficient to carry out the normal physiological functions.
Moreover, insulin resistance is another hindrance for insulin to carry on its appropriate
physiological function even when it is secreted normally. Hence, T2DM is managed by
2the drugs facilitating production of natural insulin from islet cells, and which tend to
reduce the insulin resistance. Though uncommon, apart from these two main types, DM
also includes maturity onset of diabetes in the young (MODY), latent autoimmune
diabetes in adult (LADA), maternally inherited diabetes with deafness (MIDD) and
gestational diabetes (Alberti et al., 1998; Holt et al., 2010).
Based on the time for a complication to develop, DM is accounted for number of chronic
and acute complications. Chronic complications comparatively take long time to develop
and are further divided in microvascular and macrovascular complications. Patients with
lower degree hyperglycemia are susceptible to develop microvascular complications.
These disorders are associated with severity and duration for hyperglycemia and include
retinopathy, nephropathy, neuropathy, diabetic foot and erectile dysfunction (Stephenson
and Fuller, 1994). Contrarily, hyperglycemia does not have such strong association with
macrovascular complications i.e. cerebrovascular and cardiovascular disorders (Holt et
al., 2010). These complications are associated with insulin resistance and might have
been brewing since pre-diabetes phase of a patient. Actual risk factors for these
disorders are hypertension, obesity and dyslipidemia. Therefore, even with fairly
controlled glycemic level, patients of DM are at risk of an eventful life which may lead
to mortality (Danaei et al., 2006; Holt et al., 2010). Apart from chronic complications,
for which DM control is a mild risk factor, acute complications are directly influenced
by glycemic control since fluctuation in blood glucose level may cause either hyper- or
hypo- glycemia (Stephenson and Fuller, 1994; Pickup and Williams, 2003; Holt et al.,
2010).
3There are two states of acute DM complications i.e. hypoglycemia and hyperglycemia.
Hypoglycemia, also known as dead-in-bed syndrome, occurs in patients while they
adjust themselves with their diabetes management plan (Tu et al., 2008). Mortality rate
due to hypoglycemia varies and fatality is usually considered as a result of
cardiovascular abnormalities induced by hypokalemia and activation of
sympathoadrenal system (Frier et al., 2011). Hypokalemia and cardiovascular
abnormalities are also observed in hyperglycemia provoked acute complications of DM.
Acute hyperglycemic conditions include Hyperglycemic Hyperosmolar State (HHS) and
Diabetic Ketoacidosis (DKA) (NIH, 1995). There is a small difference between these
states and these complications could be overlapped by Alcoholic Ketoacidosis, Lactic
Acidosis and Hyperchloremic Acidosis (Lebovitz, 1995; Chiasson et al., 2003). HHS is
a resultant state of relative insulin deficiency whereas DKA is experienced in case of
absolute insulin deficiency or profound insulin resistance. HHS and DKA differ in terms
of glucose concentration, presence of ketone bodies and serum osmolarity (Kitabchi et
al., 2006). Alcoholic ketoacidosis is seen if patient keeps consuming alcohol without
intake of food. Hyperchloremic acidosis is caused due to loss of bicarbonate ion (HCO3-)
by either gastrointestinal tract abnormality or renal failure. Lactic acidosis, observed as a
result of DKA, is actually an outcome of hypoxia. Abovementioned complications are
classified under metabolic acidosis (Dugdale, 2011).
1.1.2 Diabetic Ketoacidosis
DKA is an acute complication of DM. Its main attributes are hyperglycemia induced
ketosis which in turn, causes acidosis. Hyperglycemia may vary from 3.5 mmol · L-1 to
55 mmol · L-1 in DKA (Graham, 2008). Ketones, even found in a trace, are firm proof of
4DKA provided that arterial blood gas (ABG) pH is ≤ 7.30 and bicarbonate is ≤ 19 mmol
· L-1 (NICE, 2004; Kitabchi et al., 2006; Savage et al., 2011). These factors vary from
patient to patient and hence, there is no absolute definition of DKA (Lebovitz, 1995).
1.2 Statistics of Diabetic Ketoacidosis
1.2.1 Incidence rate of Diabetic Ketoacidosis
DKA was first documented in 1828 and subsequently, in 1854 (John, 1935). A detailed
account of DKA was given in 1886 which cited the work of various researchers
(Dreschfeld, 1886). Strikingly, all the discussed cases shared a common endpoint i.e.
death; as there was no cure for diabetic patients until the discovery of insulin. Moreover,
any rate of incidence or mortality for DKA was neither recorded nor mentioned in it.
The ultimate endpoint for DKA was death before the discovery of insulin and such
disappointment seems to be the reason of unavailability of any medical notes. First study
to report the number of DKA cases was available after the discovery of insulin in which
276 cases were studied over a period of 10 years. Six reports were published at different
occasions that discussed characteristics of DKA and its treatment (Baker, 1936).
Considering the aforementioned figure, the number of cases after the discovery of
insulin was 27.8 per year. For last three decades, the incidence rate of DKA in well
managed facilities was calculated to be around 4.6 to 13.4 patients of DKA per 1000
diabetic admissions ((Johnson et al., 1980; Faich et al., 1983; Wright et al., 1990;
Stephenson and Fuller, 1994; Umpierrez and Kitabchi, 2003). Currently, incidence rate
in developed countries is recorded to be approximately 8 patients of DKA per 1000
diabetic admissions (Henriksen et al., 2007; Weinert et al., 2012). However, situation in
5developing countries tends to be higher and up to sevenfold increase in incidence of
DKA was observed in Korea over period of 20 years (Ko et al., 2005).
1.2.2 Mortality rate of Diabetic Ketoacidosis
Number of deaths was an endpoint of nearly 90% of all diabetic coma cases that has
decreased since the discovery of insulin. First meta-analysis of 22 studies conducted
after the discovery of insulin reported 29.1 fatalities per 100 patients (Baker, 1936). This
shows a dramatic decrease of 70% in terms of mortality rate. Number of deaths was
further recorded to be reduced to 14.5 in 1958 when observed over a period of 5 years
(Skillman et al., 1958). However, a significant change has not been observed since then
as mortality rate in 2005 was reported to be 11.8% of total DKA admissions (Umpierrez
et al., 2002; Ko et al., 2005). It is notable that DKA is not an independent factor for
patient’s death. Associated complications of DM are also referred as reasons of mortality
since most DM patients are accompanied by chronic co-morbidities. Among these
associated complications, cardiovascular and renal complications are attributed to most
of the deaths (Connell and Louden, 1983).
1.2.3 Epidemiology of Diabetic Ketoacidosis
Short after the discovery of insulin, DKA was referred as a metabolic disorder of
patients with T1DM (Baker, 1936). It was considered that non-insulin dependant
diabetes mellitus (NIDDM) patients are not prone to develop DKA (Fishbein and
Palumbo, 1995) until DKA was observed more frequently in patients with T2DM
(Westphal, 1996). Moreover, DKA occurring in newly diagnosed T2DM patients was
found more severe than in previously diagnosed T2DM patients (Huri et al., 2009). It
6was also found that although the incidence of DKA in T2DM may seem less, DKA is,
however, more or less observed equally in both arms since the number of T2DM patients
exceeds T1DM patients. Moreover, obesity is considered among the greatest risks for
the development of DKA along with alcohol and drug abuse (Umpierrez and Kitabchi,
2003).
1.2.4 Precipitating causes of Diabetic Ketoacidosis
Infection, non-adherence to DM management plan and new onset of diabetes are
accountable for 70% of DKA cases. Non-adherence relates to deliberate omission of
medicines intended for management of DM and, in terms of dietary plan and exercise,
also includes patients’ behavior towards the life style modification (Lutfey and Wishner,
1999). Around 90% of non-adherent patients show negligence to medication and/or
lifestyle modification (Adibah and Ali, 1998). However, the studies reporting non-
adherence of DKA patients toward DM management plan do not provide any data
related to patients’ adherence i.e. Morisky Scale (Weinert et al., 2012). Similarly,
respiratory and urinary tract infections account for up to 30 to 50% of all DKA episodes
whereas gastrointestinal complication is accountable to 15% of them (Lebovitz, 1995;
Umpierrez and Kitabchi, 2003). Apart for these, infection leading to DKA is also
reported during post-operation time at the hospital. Moreover, catecholamines released
due to infection induced stress also hinder peripheral glucose utilization and promote
liver glucose production (McGuinness, 2005). Acute hyperglycemia in such scenario
facilitates production of ketone bodies and hence, causes DKA (Grimaud and Levraut,
2001). However, an elevated white blood count (WBC) used to interpret infection in
published reports might indicate dehydration instead of infection with out any data on
7microbial smear (Huri et al., 2009; Tan et al., 2012). Likewise, new on-set of diabetes
splits around 30% of DKA cases and it is well noted that these cases most commonly
occur in T2DM patients (Kitabchi et al., 2006). However, presentation of new diagnosis
of DM as a DKA patient is noted by some researchers as atypical DM, and ketosis prone
diabetes by others (Lebovitz, 1995; Kitabchi et al., 2006). Hence, all these three factors
remain debatable precipitating factors for a DKA episode.
Traumatic conditions such as head injury, stroke or myocardial infarction also contribute
in development of DKA. It is believed that elevation in level of counter-regulatory
hormones and decreased intake of water are the reasons for development of DKA
(Laffel, 1999; Stewart, 2004; Kitabchi et al., 2008b; Tu et al., 2008). Drugs affecting
normal carbohydrate metabolism i.e. thiazide diuretics, second generation anti-
psychotics and corticosteroids also precipitate hyperglycemia and eventually, DKA
(Kitabchi et al., 2008b; Holt et al., 2010; Hall and Guyton, 2011). This is especially
observed in young patients with T1DM, and is exacerbated if eating disorder is found.
Apart from these precipitating factors, 2 – 10% of DKA hospitalizations are recorded
without any underlying cause (Umpierrez and Kitabchi, 2003; Stewart, 2004; Kitabchi et
al., 2006).
1.3 Pathophysiology of Diabetic Ketoacidosis: the cascade of events
Acute hyperglycemia triggers a cascade of events that lead to an episode of DKA as
depicted in figure 1.1. Acute hyperglycemia is observed as a result of either decreased
production of insulin by pancreatic β-cells or compromised activity of insulin receptor at
cellular level. In some cases, both of these may occur simultaneously. This deregulation
8Figure 1.1 Cascade of events involved in DKA. 1) Insulin deficiency causes starvation in cell and hyperglycemia in extracellular compartment causing osmotic diuresis. 1-a) & 1-b) Brain and
pancreas receive starvation signals from cell. 1-c) Counter-regulatory hormones and glucagon are released from brain and pancreas, respectively. 2) Cell produces tissue sensitive lipase
(TSL). 2-a) Beside TSL, adipocyte itself produces hormone sensitive lipase (HSL). 2-b) Lipase converts triglycerides to free fatty acids (FFAs). 2-c) FFAs are transported to hepatocyte
where carnitine palmitoyltransferase 1 (CPT 1) shuttle pass them in mitochondrion. 3-a) FFAs undergo oxidation to give Acetone and β-Hydroxybutyric acid (ketone bodies). 3-b) Ketone
bodies are transferred to starved cell. 3) Starved cell consume ketone bodies as a source of energy by using them in tricarboxylic acid (TCA) cycle. 4) Ketone bodies are released to systemic
circulation for excretion. 4-a) Acetone is exhaled and hydrogen (H+), yielded from acetoacetic acid & β-hydroxybutyric acid, reacts with bicarbonate (HCO3-) and depletes buffer base to form
water (H2O) and carbon dioxide (CO2) and hence, cause acidosis. 4-b) When in kidney, ketone bodies exhaust the water and electrolytes of the body while sodium (Na+) and potassium (K+)
are extensively lost due to increased H+ retention.
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9causes inadequate transportation of glucose from serum to the cell and develops a state
of starvation at cellular level. In turn, body satisfies its energy requirements by utilizing
adipose tissue which involves multiple metabolic pathways and results in acute
metabolic derangement (Chiasson et al., 2003; Charfen and Fernandez-Frackelton,
2005). Glucose is the chief source of energy and its concentration and utilization is
regulated by insulin and glucagon. Insulin controls consumption of glucose and piles up
excess of glucose in form of glycogen. On the other hand, when body is short of glucose,
glucagon catabolizes glycogen back to glucose. This process is altered in two ways
which trigger DKA: 1) In case of relative insulin deficiency, when available glucose is
not able to enter a cell i.e. insulin resistance and 2) In case of absolute insulin deficiency
(Holt et al., 2010). As a reaction, glucagon, catecholamines and cortisol increase
production of glucose via glycogenolysis and gluconeogenesis in liver (Foster and
McGarry, 1983; Cahill, 2006; Barth et al., 2007).
On the other hand, disturbed levels of insulin, glucagon and catecholamines hinder
glucose absorption by peripheral tissues (Roden, 2004; Barth et al., 2007). Increased
hepatic glucose production and decreased peripheral glucose utilization cause
pathogenic hyperglycemia in DKA. This hyperglycemia alters osmotic state and causes
osmotic diuresis and dehydration All these factors decrease glucose clearance and
further exacerbate hyperglycemia (Kitabchi et al., 2001; Umpierrez and Kitabchi, 2003;
Stewart, 2004).
An enzyme, hormone sensitive lipase (HSL), is activated by low level of insulin as
shown in figure 1.2. Beside insulin, high levels of catecholamine and cortisol also
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contribute in activation of lipase (Laffel, 1999; Kraemer and Shen, 2002; Stojanovic and
Ihle, 2011).  HSL deactivates  perilipin A and facilitates consumption of triglycerides to
form free fatty acids (FFA). These FFA are converted to ketone bodies once they reach
liver and are released into the circulation (Laffel, 1999; Stojanovic and Ihle, 2011). This
process, ketogenesis, contributes to clinical condition of ketosis and is further influenced
by the increase in glucagon levels. Within a hepatocyte, FFA in form of coenzyme A are
readily transported across mitochondrial membranes with help of carnitine
palmitoyltransferase (CPT) I as referred in figure 1.3.
Perilipin
Free Fatty Acids + Glycerol
Hormone Sensitive Lipase
(-), 1
(-), 2
Triglycerides
(-), 3
Figure 1.2 Natural barrier of insulin on ketosis.
(1) Perilipin restrains production of free fatty
acids from triglycerides. (2) Hormone-Sensitive
Lipase (HSL) phosphorylate perilipin and thus,
inhibits its function. (3) Activity of HSL is then
controlled by insulin when it is dephosphorylated
by insulin. Hence insulin, via natural mechanism,
inhibits the production of ketone bodies.
Insulin
(-)
Acetyl CoA + Oxaloacetate       TCA
                    Cycle
Pyruvate
Acetyl CoA
Carboxylase
Malonyl CoA Acetyl CoA
Triglycerides
 Perilipin
                   Lipase
Free Fatty Acids
Glucose
  Glucagon
                       Insulin
Glycogen
CPT-1
Figure 1.3 Natural role of insulin in liver. Acetyl CoA is formed by 2 processes; 1) β-oxidation of free
fatty acids (FFA), and 2) Glycolysis. Acetyl CoA undergoes condensation with oxaloacetate, which is
yielded from pyruvate during glycolysis, and is consumed in tricyclicacid (TCA) cycle. Mild fasting or fat
rich diet, result in increased production of acetyl CoA which is diverted out of mitochondrion and is
converted to malonyl CoA. Acetyl CoA carboxylase is chief enzyme for this conversion and insulin
restricts its decomposition. Malonyl CoA inhibits carnitine polymaltoyl transferase-1 and thus, blocks the
entry of FFA into the mitochondrion resulting in maintenance of homeostasis.
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CPT I is activated by glucagon and it helps in esterification of coenzyme A into carnitine
(Laffel, 1999; Casteels and Mathieu, 2003). Once inside, CPT II reverts it to fatty acyl
coenzyme A which undergoes β-oxidation to produce acetyl coenzyme A (CoA). Acetyl
CoA is then consumed in production of β-hydroxybutyric acid and acetoacetic acid in
presence of nicotinamide adenine dehydrogenase (NADH) and is responsible for
acidosis in DKA (Laffel, 1999; Umpierrez and Kitabchi, 2003).
Homeostatically, pH is maintained as these acids dissipate by donating a hydrogen ion
which is readily accommodated by the plasma bicarbonate ions. However, production
rate of these acids is much higher than the rate of their utilization in DKA and hence,
these acids get accumulated in the body. As a result, pH of plasma shifts toward anionic
system due to reduced availability of bicarbonate ions (Laffel, 1999; Stojanovic and
Ihle, 2011).
1.4 Clinical presentation of Diabetic Ketoacidosis’ patient: sign and symptoms
in relation with cascading events
1.4.1 Hyperglycemia induced sign and symptoms
Persistent and acute hyperglycemia is foremost responsible for dehydration in DKA as
illustrated in figure 1.4. Initially, excess glucose in the plasma encourages flow of water
from the tissue toward extracellular space. It helps to maintain the osmotic pressure at
expense of dehydration at cellular level. Furthermore, body tends to clear the excess of
circulating glucose via kidneys and thus, water is lost alongside surplus glucose
(Chiasson et al., 2003; Umpierrez and Kitabchi, 2003). Meanwhile, ketones remain
equally accountable for dehydration as they are also excreted via renal route. However,
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Pathophysiology Systemic Effects Metabolic Derangement Presenting Features
Decreased Insulin
Production
Or
Insulin Resistance
Increased Production of;
Hormone Sensitive Lipase
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Cortisol
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Tachypnoea
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Abdominal Pain
Disorientation
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breakdown
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Figure 1.4 Signs and symptoms of DKA in relation with causative factor. Decrease in serum insulin concentration reduces peripheral glucose utilization and
enhances insulin counterregulatory hormones (ICRH). ICRHs in turn increase insulin resistance. These factors collectively enhance hepatic glucose
production and triglyceride breakdown in adipose tissue. Increased serum glucose concentration causes hyperglycemia whereas triglyceride breakdown
causes ketosis and acidosis. Sign and symptoms associated with water content of body are influenced by ketosis and hyperglycemia. Ketosis, along with
acidosis, also manipulate constitutional and central nervous system related sign and symptoms.
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it is notable that by the time concentration of ketones reaches the minimal threshold of
excretion, hyperglycemia has already had depleted adequate water content of the body.
It is therefore observed that maintaining hydration during acute hyperglycemia results in
mild to moderate episode of DKA rather than severe (Kitabchi et al., 2006). Dehydration
may take a couple of days to develop as water intake during the course of hyperglycemia
is naturally increased. Together with dehydration, patient of DKA also complains about
polyurea and polydypsia. All these are important sign and symptom which indicate acute
hyperglycemia and dehydration (Chiasson et al., 2003; Umpierrez and Kitabchi, 2003;
Stewart, 2004).
1.4.2 Hyperkalemia induced sign and symptoms
During acute hyperglycemia, body tries to maintain the osmotic pressure at the expense
of tissue and serum electrolytes. Since hyperglycemia also induces hyperkalemia,
vomiting and diarrhea are hence, commonly reported complaints in DKA (Kes, 2001).
Vomiting is a definite character of hyperkalemia whereas epigastric distress and diarrhea
may be caused by gastric infection, gastroenteritis or hyperkalemia driven smooth
muscle hyperactivity (Hoffman, 1950; Kes, 2001; Schaefer and Wolford, 2005).
Furthermore, hyperkalemia gets intense as re-entry of extracellular potassium (K+)
within the cell is mediated by insulin, which is already below the baseline during an
episode of DKA. Other factor that may partially worsen hyperkalemia is insensitivity of
cells to catecholamine-driven potassium uptake (Kes, 2001). All these factors cause
hyperkalemia which, beside the mild gastrointestinal effects, is also life threatening as it
may cause shrinking of P-wave (diastolic arrest) and elevation of T-wave (ventricular
fibrillation) (Kes, 2001; Stewart, 2004). Apart form gastric and cardiac effects,
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hyperkalemia, though to a lesser extent, is also an important phase which may cause
acidosis as it decreases secretion of H+ and re-absorption of HCO3- in the renal tubular
cells and may further exacerbate DKA (Schaefer and Wolford, 2005). However, initial
hyperkalemia is readily converted into hypokalemia as the excess of potassium is
excreted via kidney while clearing overload of glucose and ketones. General weakness is
a definite character of hypokalemia and is often reported by patient of DKA (Hoffman,
1950; Hall and Guyton, 2011).
1.4.3 Ketosis induced sign and symptoms
Ketotic/acidotic breath, tachypnoea, and in severe cases Kussmaul breathing, are distinct
features of DKA (Laffel, 1999; Umpierrez and Kitabchi, 2003). Excretory route for
ketone bodies is via kidney in DKA and the hyperglycemia induced dehydration makes
their clearance even difficult. Second route of excretion for ketone bodies is via
respiration and once the acids (acetone specifically) reach lungs, they are readily exhaled
and hence easily smelled in the breath of DKA patient (Laffel, 1999). Naturally, ketone
bodies are weak acids and they quickly dissociate to give a H+ ion. This H+ ion is readily
absorbed by the body’s natural buffer system i.e. bicarbonates to form carbonic acid.
Upon reaching the lungs, carbonic acid is promptly converted to CO2 and H2O which are
then exhaled. In DKA however, respiratory system tries to be consistent with production
of ketone bodies and clearance of carbonic acid and therefore, the rate of respiration is
increased i.e. tachypnoea (Charfen and Fernandez-Frackelton, 2005; Umpierrez and
Kitabchi, 2003). With the progress of DKA episode, it becomes difficult for body to
cope with this equilibrium as bicarbonates are preoccupied with the overwhelming
production of H+ ion from ketone bodies. Meanwhile, metabolic acidosis stimulates
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respiratory centre in the brainstem and peripheral chemoreceptors, and provokes
hyperventilation. This causes a decrease in partial pressure of CO2 which eventually
drags the body toward an anionic system and further decreases the plasma pH (Chiasson
et al., 2003; Stewart, 2004; Yi et al., 2010). The respiratory system gets compensated,
breathing gets deep and laboring, and patient is observed as gasping for air. This
phenomenon is known as Kussmaul breathing i.e. when blood gases have low partial
pressure of CO2 in concurrence with low bicarbonate due to forced increased respiration
(Kitabchi and Wall, 1995; Chiasson et al., 2003).
1.4.4 Acidosis induced sign and symptoms
Apart from respiratory distress, abdominal pain, which may occasionally be covering an
acute abdomen, is a symptom often reported by patients with DKA (Dreschfeld, 1886;
Baker, 1936; Umpierrez and Freire, 2002). Severe metabolic acidosis is usually
associated with gastrointestinal signs which also include abdominal pain especially in
patients with a history of alcohol or cocaine abuse. However, it is not certain that
whether or not, abdominal pain is connected with the severity of hyperglycemia or
dehydration as well (Umpierrez and Freire, 2002).
1.5 Laboratory values; Acid-Base and electrolyte homeostasis
1.5.1 Acid-Base homeostasis in Diabetic Ketoacidosis
Ketosis is a natural metabolic process that causes overproduction of β-hydroxybutyric
acid and acetoacetic acid in DKA. Both of these acids dissociate readily, give a H+ ion
which binds with HCO3- at physiological pH and hence, cause a decrease in the level of
HCO3- (Laffel, 1999; Chiasson et al., 2003; Stojanovic and Ihle, 2011). Ketone bodies
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themselves circulate in the anionic form and this causes a widening of anion gap. On
average, the anion gap is 6 mmol · L-1 and lies within 3 – 11 mmol · L-1. Anion gap is
used as a measurement for metabolic acidosis in DKA and is based upon the difference
between cations and anions measured by formula Na+ – (Cl– + HCO3–) (Kitabchi et al.,
2006). Even with the substantial clearance of ketone bodies via kidney, high
concentrations of acetoacetic acid and β-hydroxybutyric acid in DKA consume the
bicarbonate ion and thus, widening the anion gap.
1.5.2 Electrolytes’ homeostasis in Diabetic Ketoacidosis
The body is around 5 – 7 L deficient of total water in DKA which on average, is nearly
10–15% of body weight (Kitabchi et al., 2006). Naturally, body is deficient of most
abundant electrolytes i.e. sodium, chloride and potassium. During the early state of
DKA, plasma values for sodium, potassium and chloride are elevated due to the initial
intracellular-to-extracellular electrolyte movement. However, due to frequent loss of
water and electrolytes via kidney, lower serum values of these electrolytes are detected
by the time patient reports for medical advice. The minimum threshold value for these
electrolytes is 135 mmol · L-1, 98 mmol · L-1 and 3.5 mmol · L-1 respectively, whereas
average shortfall for these electrolytes in DKA is usually 5–13 mmol · kg-1 body weight
for sodium, and 3 – 7 mmol · kg-1 each for chloride and potassium (Jones, 1994;
Kitabchi and Wall, 1995). As for sodium, serum sodium concentration is usually low to
normal at the time of presentation and in some cases, hyperlipidemia may even cause
hypernatremia at time of presentation (Umpierrez and Kitabchi, 2003). Similar
characteristics are observed with chloride ion. Both these ions are found abundantly in
human serum and may not cause serious effects if mild hypo– and hyper– values are
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observed. These events however, do not appear easier while evaluating potassium as
hyperglycemia prone shift of water forcefully evacuates potassium from intracellular to
extracellular space and further subjects to renal clearance in the presence of
hyperglycemia, acidosis and insulinopenia. Moreover, poor oral intake of potassium,
vomiting and secondary hyperaldosteronism may further exacerbate potassium levels
(Kes, 2001; Umpierrez and Kitabchi, 2003; Chiasson et al., 2003).
1.5.3 Miscellaneous profiles in Diabetic Ketoacidosis
Beside the above mentioned biochemical profiles, some presenting characteristics are
also considered in the continuum of DKA. Elevated HbA1C is an indicator for poor
adherence of patient with diabetic management and its use as a marker of non-adherence
is helpful if there is no underlying cause found for DKA episode (Kitabchi et al., 2006).
Euthermia at the time of admission is also an indicator for patient not carrying any
infection (Sawyer, 1903; Hockenhull et al., 2012). However, this may not be used as a
distinctive tool because hypovolemia may still cause hypothermia in presence of
infection (Kitabchi and Nyenwe, 2006). Contrarily, though hypothermia is not a definite
character of DKA, it may seem helpful to detect the progress in condition of patient as
the patient with deteriorating condition may also develop hypothermia (Kitabchi et al.,
2006). Moreover, infection should only be ruled in/out by a proper microbiological
profile as most of the DKA patients show leukocytosis at the time of admission.
However, there may not be any pathological organism found in microbiological
profiling (Stewart, 2004; Kitabchi et al., 2006). Such phenomenon is observed due to
severe dehydration secondary to hyperglycemia which may give false referral towards
an infection (Bacon et al., 1922; Umpierrez and Kitabchi, 2003).
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1.6 Treatment goal for Diabetic Ketoacidosis management
Correction of dehydration, electrolyte imbalances, and hyperglycemia are of prime
management importance for successful treatment of DKA. DKA patients undergo stress
due to depleted fluid volume and metabolic derangement and hence, should
simultaneously receive intravenous fluid hydration, electrolyte replacement and insulin
administration (Stewart, 2004; Kitabchi et al., 2006; Savage et al., 2011). Any specific
treatment should be decided later in accordance with precipitating cause. Frequent
biochemical monitoring of patients should be carried in order to avoid any iatrogenic
complication resulting from the treatment (Stewart, 2004; Savage et al., 2011). Serum
electrolytes, glucose and blood gases are considered important profiles to observe.
Provided the etiology of DKA, treatment goals should be set on the following
parameters;
1.6.1 Rehydration: as water moves toward the extra–cellular space because of
increased glucose concentration. Moreover during the renal clearance of glucose, water
and electrolytes are lost via urine. Loss of water may be observed around 100 ml · kg-1
of body weight (Chiasson et al., 2003; Kitabchi et al., 2006). Hence, rehydrating the
patient enhances transportation of physiologically important ions within the body. It
further improves the gaseous exchange in lungs and the renal function thereby resolving
respiratory distress and facilitating excretion of metabolites and remains via urine.
1.6.2 Euglycemia: as an episode of DKA is triggered by hyperglycemia, hence its
timely correction is important. While achieving euglycemia, insulin also redirects the
deranged metabolic processes towards homeostasis. As depicted in figure 1.2 and 1.3,
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insulin decreases catabolism of adipose tissue, inhibits CTP-1 shuttle and promotes
glycogenesis thereby partially resolving crisis of ketosis and acidosis (Laffel, 1999;
Casteels and Mathieu, 2003). Gradual decrease in the production of ketone bodies
causes scarcity of acids. Hence, pH shifts toward normalization, level of bicarbonate is
increased, and partial pressure of CO2 and O2 are improved (Lebovitz, 1995; Stewart,
2004).
1.6.3 Correction of electrolyte imbalance: as initial hydration only relieves the stress
caused by the depletion of electrolytes during initial phase of DKA. However, insulin
mediated re-entry of electrolytes form extracellular to intracellular space sets a new
stress (Kes, 2001; Charfen and Fernandez-Frackelton, 2005). Close monitoring of the
electrolytes and plasma components during initial phase of management is therefore
equally mandatory. Sodium chloride in form of normal saline is used to maintain the
volume of plasma. Occasionally, potassium, calcium and phosphates could also be
added to avoid tetany and cardiac issues (Umpierrez and Kitabchi, 2003; Stewart, 2004).
1.6.4 Eradication of underlying cause: as urinary and respiratory tract infections are
among precipitating causes for DKA in around 50% of cases (Lebovitz, 1995;
Umpierrez and Kitabchi, 2003). Owing to the fact that leukocytosis with temperature
spike may indicate infection, antibiotic should still rationally be given to DKA patient.
Such impression of infection could be a mere aggregation of dehydration. Extensive care
is required in DM patients with compromised renal and cardiac function and imbalanced
electrolytes should be translated skillfully. Choice of medication is important in case of
such co-morbidities which otherwise may give conflicting biochemical values. However,
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swift improvement in hydration and glucose level enhance the chances of addressing
underlying cause of DKA within 24hours (Kitabchi et al., 2008b).
1.7 Treatment protocol for Diabetic Ketoacidosis management
There have been number of guidelines which encompass a treatment protocol for the
management of DKA. Commonalities and differences among these protocols are
discussed below.
1.7.1 Intravenous fluid expansion
Hypovolemia remains the initial goal in management of DKA. Fluid expansion restores
vascular volume, enhances tissue perfusion and dilutes concentration of insulin counter-
regulatory hormones (ICRH) and glucose. Moreover, it reduces adrenergic stimulation,
DKA induced peripheral insulin resistance and haemoconcentration. It also improves
exchange of ions and metabolites at tissue level and renal perfusion (Charfen and
Fernandez-Frackelton, 2005). Commenced trails, meta analysis of such trails and
recommended guidelines support the use of intravenous (IV) fluid replacement as a
starter (Stewart, 2004; Barone et al., 2007). However, there has not been a uniform
formula to calculate the rate of administration of the IV fluid. It is a consensus that the
rate of administration of IV fluid for initial couple of hours should be rapid in order to
achieve hemodynamic stability and maintain cardiac output (Charfen and Fernandez-
Frackelton, 2005). It should later be decreased to a rate where the total body water
(TBW) deficit is compensated over 24h (Umpierrez and Kitabchi, 2003).
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Normal saline (NS) is the recommended IV fluid to initiate resuscitation. Depending
upon cardiac function and serum electrolytes, either 0.9 or 0.45% NS could be used. The
TBW deficit for an average weight patient is around 5 to 8 liters (0.6 · weight · [1-140 ·
serum sodium-1]) (Stewart, 2004). Therefore, the rate of IV fluid infusion should be set
so that 50% of TBW loss is recovered in 3rd part of the day and remaining, subsequently
through the rest (Charfen and Fernandez-Frackelton, 2005; Kitabchi et al., 2004; Bhave
and Neilson, 2011). Some guidelines suggest that around 15 – 20 mL · kg-1 body weight
· hour-1 of NS should initially be administered. It can then be reduced to 4 – 14 mL · kg-1
body weight · hour-1 (NICE, 2004; Kitabchi et al., 2006; Embong and Yahya, 2009;
Savage et al., 2011). One to two liters of bolus IV fluid infusion is also recommended
for rapid correction of hypovolemia. After initial infusion, this rate should be cut to half
until the patient is found stable haemodynamically and subsequently, 0.45% NS should
be used to cover the deficit of free water content of blood (Lebovitz, 1995; Kitabchi et
al., 2006). Other guidelines allow using 0.9% NS only if blood pressure is below 90
mmHg as in case of severe hypovolemia, there might be a greater loss of serum Na+
ions. A complete biochemical profile of the serum electrolytes would be helpful to
assess the use of IV fluid (Savage et al., 2011). It is also recommended that once the
value of corrected serum sodium has been retrieved, normal to high value of Na+ should
be reciprocated by using 0.9% NS and if found to be low, 0.45% NS should be
administered (Lebovitz, 1995; Stewart, 2004; Kitabchi et al., 2008b).
It is suggested that target for blood glucose level (BGL) should be set between 150 and
200 mg · dL-1 until the resolution of ketosis and acidosis. In order to avoid
hypoglycemia during this phase, NS should be replaced with 5% dextrose. It could be
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increased to 10 or 20% dextrose, provided that the BGL falls below 100 mg · dL-1
(Charfen and Fernandez-Frackelton, 2005). Use of 2 IV drips is suggested to avoid
sudden change in BGL. While each bag should have same electrolyte concentration, one
bag may contain dextrose in it (Grimberg et al., 1999). Summarizing the consensus
among the guidelines, notable points are that initial resuscitation should be at a fast rate;
0.45 or 0.9% NS could be used for resuscitation depending upon the cardiac and renal
profile; NS should be replaced with dextrose so as to maintain the BGL.
1.7.2 Insulin therapy
Insulin therapy improves the BGL, inhibits gluconeogenesis and decreases lipolysis. It
ceases the production of ketone bodies thereby reducing acidosis that occurs in DKA
(Laffel, 1999; Stewart, 2004; Cahill, 2006). However, the time required achieving
homeostatic values of glucose, bicarbonate and pH vary in each patient and depends
upon the biochemical levels found at the time of admission and the precipitating cause.
Physiological reduction of BGL by insulin is 80 mg · dL-1 ·  h-1. Hence, the time to
achieve targeted BGL of 200 mg · dL-1 can be calculated as (Barone et al., 2007):
Time in minutes = Initial blood glucose (mg · dL-1) - 200/80
Estimated time for normalization of pH and bicarbonate levels is twice the time taken to
attain the BGL of 200 mg · dL-1. Comatose patients may regain consciousness following
normalization of pH and bicarbonate. Reduction in plasma osmolarity should also be
monitored. It should not exceed the rate of 3 mOsm · kg-1 of body weight · hour-1 as it
may trigger cerebral edema (Barone et al., 2007). Some studies also suggest that in such
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patients, BGL should not be reduced to less than 250 mg ·  dL-1 until the patient is lucid
and oriented. Reason for this precaution is to avoid risk of cerebral edema and
hypoglycemia that may remain unnoticed during such condition (Chiasson et al., 2003;
Trachtenbarg, 2005).
Use of low doses of insulin in management of DKA is supported by guidelines, as the
slow delivery of continuous insulin infusion (CII) via IV route was found to be equally
effective as the fast one (Kitabchi et al., 2008a). Available trails and meta-analysis of
such data also support use of CII (Stewart, 2004). Some guidelines suggest initial bolus
IV insulin is recommended at a rate of 0.1 to 0.15 IU · kg-1 of body weight followed by
CII at a rate of 0.1 IU · kg-1 of body weight · hour-1 via infusion pumps (Kitabchi et al.,
2006; Savage et al., 2011). Other guidelines suggest a higher constant infusion rate of 2
IU · hour-1 (Embong and Yahya, 2009). In case of patients that are unresponsive to
insulin and do not show any observable change in blood pH or anion gap, DKA
management should be started with a bolus IV of 50 IU followed by the initial 10 to 20
IU as CII for some time (Fisken, 1999). NS or D5% could be used as a carrier of insulin
for CII. However, the ratio of insulin solution should be set so that each 10 mL of CII
may correspond to 1 IU of insulin (Barone et al., 2007). Notably, should insulin be
adsorbed by the rubber tubing of CII, 30 to 50 mL of early solution may be discarded
(Magee and Bhatt, 2001).
During the first hour of CII, BGL should decrease by 50 to 70 mg · dL-1 and the insulin
dose should be doubled hourly until BGL target is attained. This rate could be doubled
as 0.2 IU (Kitabchi et al., 2006) or 4 IU · hour-1 (Embong and Yahya, 2009). It is also
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suggested that IV bolus of 10 IU of insulin should be given after every hour until
euglycemia is achieved (Kitabchi et al., 2004). Nevertheless, all protocols recommend
tight glycemic control within first 24 hours because it facilitates betterment in general
condition of patient and avoids complications.
Intramuscular (IM) use of regular insulin as a substitute for CII is associated with
several drawbacks. High rate of BGL fluctuation is observed following IM
administration of insulin (Kitabchi et al., 2001; Chiasson et al., 2003; Stewart, 2004).
Patients of DKA have moderate to severe dehydration and absorption of IM insulin is
very low in peripheral tissues. Hence, it takes increased dose of insulin to achieve
euglycemia. However, as hydration improves, absorption of insulin administered via IM
route suddenly increases, which causes a sharp decline in BGL. Consequently, while
using IM as the route for insulin administration, the rate at which insulin reaches the
systemic circulation effectively is unpredictable. With BGL below 250 mg · dL-1 and
normalization of blood pH, the CII should be replaced by IM insulin (Stewart, 2004). It
is also suggested that rapid acting insulin should be divided in three doses over a period
of 24 hours and long-acting insulin should be used at night to maintain a tight BGL.
Such protocol is advised to be followed up to 72 hours after the discontinuation of CII
(Barone et al., 2007). Switching between the two routes should be done carefully. An
initial dose of rapid-acting insulin is recommended 2 hours prior to the suspension of CII
so that subcutaneous insulin adequately reaches the systemic circulation (Lebovitz,
1995). Patients with high risk co-morbidities and complications should be managed
individually. A patient with pregnancy in first trimester or a renal failure patient may
experience hypoglycemia. Contrarily, presence of infections, steroid usage and
